BioHarvest Sciences 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- BioHarvest Sciences reported 3rd quarter 2026 revenue of $7.9 million, compared with $9.1 million in the same year-ago quarter.
- Gross profit was $4.2 million, or 54% of total revenue, compared with $5.6 million, or 61%, in the same year-ago quarter; the lower margin reflected a smaller contribution from higher-margin CDMO development revenue.
- R&D expenses were $1.8 million, sales and marketing expenses were $4 million, and G&A expenses were $1.5 million in the 3rd quarter of 2026.
- Net loss was $3.3 million, or $0.15 per basic and diluted share, compared with a net loss of $2.5 million, or $0.14 per basic and diluted share, in the same year-ago quarter.
- Adjusted EBITDA loss was $2 million, compared with $400,000 in the same quarter last year.
- Cash and cash equivalents, together with bank deposits, totaled $12.5 million as of September 30th, 2026, compared with $11 million as of September 30th, 2025.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, and welcome to the BioHarvest Sciences Third Quarter 2026 Financial Results Conference Call. As a reminder, all participants are in listen-only mode. If you would like to ask a question, please press star one on your phone. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded. I will now hand the call over to Justin Meiklem, Head of Investor Relations.
Please go ahead. Greetings, and welcome to the BioHarvest Sciences Third Quarter 2026 Financial Results Conference Call.
With us on the call this morning are Dr. Zaki Rakib, Chief Executive Officer, and Bar Dichter, Chief Financial Officer. Before we begin, I would like to remind you that management will be making projections and forward-looking statements on the call today regarding future events. Any statements that are not historical facts are forward-looking statements. These statements are made pursuant to and within the meaning of the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. We encourage you to review BioHarvest Sciences' SEC filings, including the company's most recent Form 6-K, which identify risks and uncertainties that may cause future actual results or events to differ materially. These filings can be found on the company website, as well as the SEC's website at www.sec.gov.
Please note that the forward-looking statements made during today's call speak only to the date they are made, and BioHarvest Sciences undertakes no obligation to update them. With that, I would like to now turn the call over to Dr. Zaki Rakib, Chief Executive Officer of BioHarvest.
Thank you, Justin, and thank you all for joining us. Our third quarter results reflect a period of deliberate transition. We took a more selective approach to customer acquisition for VINIA, scaling back lower return activities. We also concentrated our CDMO resources on advanced programs with near-term manufacturing potential. Those decisions affected revenue in the quarter, while lower CDMO development revenue also weighed on consolidated gross margin. We are aligning our capital allocation and operating expenses with our commercial priorities. Preserving cash liquidity is our foremost near-term priority. We intend to grow VINIA with better economics and focus our CDMO development capabilities on programs that we believe can reach manufacturing sooner. BioHarvest's Botanical Synthesis platform technology enables us to produce plant-based ingredients without growing the plant itself. We apply that technology through our VINIA products business and our CDMO development and manufacturing business.
Our task now is to translate the capabilities we built into better operating results and stronger cash economics. Today, we will explain the quarter's results and the priorities shaping our plans for 2027. Cash preservation is central to those plans, alongside the investments required to advance our most important commercial opportunities. Bar will begin with the financial results, and I will then discuss our business priorities.
Bar? Thank you, Zaki, and good morning, everyone.
I will provide you with a summary of our financial results. A full breakdown is available in our SEC filings and in the press release that crossed the wire before market opened today. Please note that all figures are in USD unless stated otherwise. Revenues for the third quarter of 2026 were $7.9 million compared to $9.1 million in the same year-ago quarter. The decrease reflects our planned shift to profitable growth in the product business unit and the timing of CDMO development revenue. Cost of revenue was $3.6 million compared to $3.5 million for the same period last year. Gross profit in the third quarter of 2026 was $4.2 million, or 54% of total revenue, as compared to $5.6 million, or 61% of total revenue, in the same year-ago quarter.
The change reflects the mix of revenue in the quarter, which was weighted towards the product business unit revenue, with a lower contribution from higher-margin CDMO development revenue. R&D expenses totaled $1.8 million for the third quarter of 2026, compared to $1.4 million for the same period last year. The increase was primarily driven by higher technology development expenditures within the CDMO service business unit due to the need to accelerate the development of the rare fragrance composition in light of the supply agreement that was signed. Sales and marketing expenses totaled $4 million for the third quarter of 2026, compared to $4.1 million for the same period last year. G&A expenses totaled $1.5 million for the third quarter of 2026, compared to $900,000 for the same period last year.
The increase is primarily driven by a one-time income of $400,000 recognized during the third quarter of 2025, which offset expenses in the comparative period. Net losses for the third quarter of 2026 totaled $3.3 million, or $0.15 per basic and diluted share, compared to a net loss of $2.5 million, or $0.14 per basic and diluted share, for the same period last year. Adjusted EBITDA loss, a non-IFRS measure, totaled $2 million compared to $400,000 for the same quarter last year. Under the two-lens approach, the Adjusted EBITDA loss of the CDMO service division is $1.4 million and $600,000 for the product division for the third quarter of 2026, compared to a loss of $200,000 and $200,000 in the same year-ago quarter, respectively.
Cash and cash equivalents, together with bank deposit as of September 30, 2026, totaled $12.5 million compared to $11 million as of September 30, 2025. I would like now to pass the call back to Zaki.
Thank you, Bar. I want to begin with VINIA. Our objective is to build a business that can grow while making a stronger contribution to the company's financial position. That requires us to be more selective about how we acquire customers, improve retention, and evaluate marketing investment against contribution margin. Toward the end of the second quarter, we began implementing changes to VINIA's marketing and sales strategy to improve profitability. We deliberately reduced customer acquisition activity where returns did not meet our objectives. We anticipated a moderate decline in revenue as part of that transition, and we expect the benefits of these changes, together with revenue growth, to begin becoming evident in the first quarter of 2027. In September, we launched single-dose VINIA Daily Chews. This format complements our existing portfolio and broadens customer choice. It has so far shown all the hallmarks of a premium, high-value winner.
Turning to the CDMO. We are concentrating development resources on a smaller group of programs with a clearer path to manufacturing and commercialization. During the quarter, we prioritized the rare fragrance program, for which a supply agreement has been signed, over progress on other development projects. This allocation of resources reflected our assessment of the program's future profitability potential and contributed to the limited external development revenue recognized in the quarter. We recognize the near-term financial impact of that decision. The commercial rationale is to focus our technical resources where we believe they can generate the greatest long-term value. The outcome will depend on successful development, production readiness, and execution with our partners. In August, we signed our CDMO division's first manufacturing and supply agreement. This exclusive agreement extends an existing development program for a rare, high-value plant-based fragrance ingredient.
The source plant is endangered because of over-harvesting and habitat loss. The ingredient is among the world's most valuable fragrance raw materials, with premium grades commanding prices above tens of thousands of dollars per kilogram. Our program seeks to provide a manufacturing pathway using Botanical Synthesis. We completed stage 1 in March and initiated stage 2 in May. Stage 2 is expected to be completed within six months to nine months of its initiation. The supply agreement provides for anticipated production of 20 tons of the fragrance composition, and we anticipate that limited production could begin in the first half of 2027, subject to successful completion of development. As described in our earnings release, we estimate that the agreement could generate $20 million-$30 million of revenue over 2027 and 2028.
This is an estimate tied to the expected execution of the program, and the timing and amount of revenue remain subject to development and commercial execution. Our 2027 priorities include completing development of three advanced projects: the rare fragrance ingredient, the saffron compound, and the natural sweetener molecule for Tate & Lyle. We also aim to license our unique developed molecules assets. Turning to our manufacturing strategy, we intend to add manufacturing capacity gradually in phases aligned with demonstrated demand. This approach is designed to preserve cash while supporting commercial requirements. We also plan to reduce fixed operating costs, including through consolidation of development sites in 2027. Let me now address our updated outlook for 2026. The actions we began taking at the start of the third quarter have changed our expectations for this year as we position the business for 2027.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
6 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
